

BIOCON GROUP

FACT SHEET

June - 2017

BIOCON LIMITED (CONSOLIDATED)**BALANCE SHEET****(Rs Cr)**

	June 30, 2017	March 31, 2017
ASSETS		
Non-current assets		
(a) Property, plant and equipment	3,506	3,553
(b) Capital work-in-progress	613	533
(c) Investment property	1	1
(d) Goodwill	26	26
(e) Other intangible assets	43	46
(f) Intangible assets under development	342	306
(g) Investments in associates and a joint venture	46	42
(h) Financial assets	-	-
Investments	146	146
Derivative assets	113	109
Other financial assets	20	20
(i) Income-tax asset, net	93	90
(j) Deferred tax asset, net	194	197
(k) Other non-current assets	305	278
	5,448	5,347
Current assets		
(a) Inventories	718	635
(b) Financial assets		
Investments	1,247	1,065
Trade receivables	830	883
Cash and cash equivalents	517	710
Other bank balances	339	334
Derivative assets	103	106
Other financial assets	158	155
(c) Other current assets	148	159
	4,060	4,047
TOTAL	9,508	9,394
EQUITY AND LIABILITIES		
Equity		
(a) Share capital	300	100
(b) Other equity	4,620	4,738
Equity attributable to equity holders of the Company	4,920	4,838
Non-controlling interest	395	376
	5,315	5,214
Non-current liabilities		
(a) Financial liabilities		
Borrowings	2,071	2,108
Derivative liability	5	6
Other financial liabilities	-	-
(b) Provisions	37	36
(c) Other non-current liabilities	340	352
	2,453	2,502
Current liabilities		
(a) Financial liabilities		
Borrowings	219	97
Trade payables	799	740
Derivative liability	6	6
Other financial liabilities	316	326
(b) Short-term provision	50	47
(c) Income tax liability, net	105	96
(d) Other current liabilities	245	366
	1,740	1,678
TOTAL	9,508	9,394

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q1 FY 18	Q1 FY 17	Variance IndAS
INCOME			
Small molecules	363	435	-17%
Biologics	184	161	15%
Branded formulations	130	158	-17%
Research services	291	275	6%
Inter-segment	(34)	(37)	-5%
Revenue from operations #	934	992	-6%
Other income	54	41	32%
TOTAL REVENUE	988	1,033	-4%
EXPENDITURE			
Material & Power costs	410	438	-6%
Staff costs	193	164	18%
Research & Development expenses*	58	52	13%
Other expenses	81	75	7%
Manufacturing, staff & other expenses	742	729	2%
EBITDA	246	304	-19%
Interest & Finance charges	16	6	182%
Depreciation & Amortisation	99	66	49%
Share of profit in JV	(4)	(5)	-24%
PBT BEFORE EXCEPTIONAL ITEM	135	237	-43%
Exceptional item, Net	-	-	-
PBT	135	237	-43%
Taxes	38	54	-32%
NET PROFIT BEFORE MINORITY INTEREST	97	183	-47%
Minority interest	16	16	4%
NET PROFIT FOR THE PERIOD	81	167	-51%
EPS Rs.	1.4	2.8	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	8	17	
* Gross Research & Development expenses	96	92	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q1 FY 18	Q4 FY 17	Variance IndAS
INCOME			
Small molecules	363	395	-8%
Biologics	184	163	13%
Branded formulations	130	131	0%
Research services	291	283	3%
Inter-segment	(34)	(41)	-15%
Revenue from operations #	934	931	0%
Other income	54	43	25%
TOTAL REVENUE	988	974	1%
EXPENDITURE			
Material & Power costs	410	383	7%
Staff costs	193	178	9%
Research & Development expenses*	58	65	-11%
Other expenses	81	117	-32%
Manufacturing, staff & other expenses	742	743	0%
EBITDA	246	231	6%
Interest & Finance charges	16	5	222%
Depreciation & Amortisation	99	73	36%
Share of profit in JV	(4)	(6)	-25%
PBT BEFORE EXCEPTIONAL ITEM	135	159	-15%
Exceptional item, Net	-	-	-
PBT	135	159	-15%
Taxes	38	3	1404%
Taxes on exceptional item	-	8	-100%
NET PROFIT BEFORE MINORITY INTEREST	97	148	-34%
Minority interest	16	21	-22%
NET PROFIT FOR THE PERIOD	81	127	-36%
EPS Rs.	1.4	2.1	
<i>Note: The figures are rounded off to the nearest crores, percentages are based on absolute numbers</i>			
# Licensing Income	8	16	
* Gross Research & Development expenses	96	98	